The stock of Omeros Corporation (OMER) has seen a -3.32% decrease in the past week, with a -6.19% drop in the past month, and a -1.94% decrease in the past quarter. The volatility ratio for the week is 5.37%, and the volatility levels for the past 30 days are at 5.90% for OMER. The simple moving average for the past 20 days is -1.62% for OMER’s stock, with a -1.57% simple moving average for the past 200 days.
Is It Worth Investing in Omeros Corporation (NASDAQ: OMER) Right Now?
The 36-month beta value for OMER is also noteworthy at 1.48. There are mixed opinions on the stock, with 4 analysts rating it as a “buy,” 2 rating it as “overweight,” 1 rating it as “hold,” and 0 rating it as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for OMER is 55.36M, and at present, short sellers hold a 21.39% of that float. The average trading volume of OMER on October 04, 2024 was 328.38K shares.
OMER) stock’s latest price update
The stock of Omeros Corporation (NASDAQ: OMER) has decreased by -5.72 when compared to last closing price of 4.02.Despite this, the company has seen a loss of -3.32% in its stock price over the last five trading days. seekingalpha.com reported 2024-08-10 that Omeros Corporation (NASDAQ:OMER ) Q2 2024 Results Earnings Conference Call August 7, 2024 4:30 PM ET Company Participants Jennifer Cook Williams – Investor Relations, Cook Williams Communications, Inc. Gregory Demopulos – Chairman and Chief Executive Officer David Borges – Chief Accounting Officer Catherine Melfi – Chief Regulatory Officer Nadia Dac – Chief Commercial Officer Andreas Grauer – Chief Medical Officer Steven Whitaker – Vice President-Clinical Development Conference Call Participants Steve Brozak – WBB Securities Olivia Brayer – Cantor Fitzgerald John Gionco – Needham & Company Operator Good afternoon and welcome to today’s earnings call for Omeros Corporation. At this time, all participants are in a listen-only mode.
Analysts’ Opinion of OMER
Many brokerage firms have already submitted their reports for OMER stocks, with UBS repeating the rating for OMER by listing it as a “Neutral.” The predicted price for OMER in the upcoming period, according to UBS is $2 based on the research report published on December 08, 2022 of the previous year 2022.
BofA Securities, on the other hand, stated in their research note that they expect to see OMER reach a price target of $3, previously predicting the price at $8. The rating they have provided for OMER stocks is “Underperform” according to the report published on November 08th, 2022.
BofA Securities gave a rating of “Neutral” to OMER, setting the target price at $4 in the report published on June 08th of the previous year.
OMER Trading at -9.77% from the 50-Day Moving Average
After a stumble in the market that brought OMER to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -33.27% of loss for the given period.
Volatility was left at 5.90%, however, over the last 30 days, the volatility rate increased by 5.37%, as shares sank -4.29% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -30.46% lower at present.
During the last 5 trading sessions, OMER fell by -3.32%, which changed the moving average for the period of 200-days by +33.45% in comparison to the 20-day moving average, which settled at $3.84. In addition, Omeros Corporation saw 15.90% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at OMER starting from Demopulos Gregory A MD, who purchase 15,000 shares at the price of $1.68 back on Nov 17 ’23. After this action, Demopulos Gregory A MD now owns 123,945 shares of Omeros Corporation, valued at $25,200 using the latest closing price.
Demopulos Peter A MD, the Director of Omeros Corporation, purchase 10,000 shares at $1.53 during a trade that took place back on Nov 15 ’23, which means that Demopulos Peter A MD is holding 208,516 shares at $15,300 based on the most recent closing price.
Stock Fundamentals for OMER
Current profitability levels for the company are sitting at:
- -136.24 for the present operating margin
- 0.4 for the gross margin
The net margin for Omeros Corporation stands at -102.52. The total capital return value is set at -0.63. Equity return is now at value -576.33, with -45.24 for asset returns.
Based on Omeros Corporation (OMER), the company’s capital structure generated 1.41 points at debt to capital in total, while cash flow to debt ratio is standing at -0.36. The debt to equity ratio resting at -3.44. The interest coverage ratio of the stock is -11.22.
Currently, EBITDA for the company is -163.61 million with net debt to EBITDA at -2.38. When we switch over and look at the enterprise to sales, we see a ratio of 484.52. The receivables turnover for the company is 0.04for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.41.
Conclusion
In summary, Omeros Corporation (OMER) has had a mixed performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
